Skip to main
RNXT

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx is a clinical-stage biopharmaceutical company with an innovative Trans-Arterial Micro-Perfusion (TAMP) therapy platform, which has the potential to significantly improve therapeutic outcomes for cancer patients undergoing treatment. With a rapidly growing number of active commercial cancer centers and strong commercialization efforts for its FDA-cleared proprietary medical device RenovoCath, the company has a strong potential for revenue growth in the near future. The recent appointment of a new CFO, positive Q1 results, and key milestones expected in the coming years add to the positive outlook for RenovoRx.

Bears say

RenovoRx is facing significant risks to their share price target as a result of balance sheet and liquidity concerns, as well as potential failures in clinical trials and regulatory approvals. Additionally, their financials and revenue projections paint a bleak picture for the company, with a projected net loss of $0.35 per diluted share in 2026. These challenges, combined with competition and changing macroeconomic factors, make for a negative outlook on RenovoRx's stock.

RenovoRx (RNXT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of Jul 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.